The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: a large, randomized, placebo …
R Westhovens, D Yocum, J Han, A Berman… - Arthritis & …, 2006 - Wiley Online Library
Objective To assess the risk of serious infections following 22 weeks of infliximab therapy,
and to further characterize the safety profile of infliximab in combination with background …
and to further characterize the safety profile of infliximab in combination with background …
Three multicenter, randomized, double‐blind, placebo‐controlled studies evaluating the efficacy and safety of ustekinumab in axial spondyloarthritis
…, F Ariel, CA Asnal, A Berman… - Arthritis & …, 2019 - Wiley Online Library
Objective To evaluate the efficacy and safety of ustekinumab in 3 randomized, placebo‐controlled
studies in patients with axial spondyloarthritis (SpA). Studies 1 and 2 included patients …
studies in patients with axial spondyloarthritis (SpA). Studies 1 and 2 included patients …
Rheumatic manifestations of human immunodeficiency virus infection
A Berman, LR Espinoza, JD Diaz, JL Aguilar… - The American Journal of …, 1988 - Elsevier
Purpose: The prevalence and characteristics of the rheumatic and extra-rheumatic manifestations
of human immunodeficiency virus (HIV) infection were determined in a prospective …
of human immunodeficiency virus (HIV) infection were determined in a prospective …
[HTML][HTML] Efficacy and safety of ixekizumab in the treatment of radiographic axial spondyloarthritis: sixteen‐week results from a phase III randomized, double‐blind …
…, M Barkham, AAB Rodriguez, A Berman… - Arthritis & …, 2019 - Wiley Online Library
Objective To investigate the efficacy and safety of ixekizumab in patients with active radiographic
axial spondyloarthritis (SpA) and prior inadequate response to or intolerance of 1 or 2 …
axial spondyloarthritis (SpA) and prior inadequate response to or intolerance of 1 or 2 …
Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial
…, J Sieper, F Morin, P Rahman, F Ariel, A Berman… - The Lancet, 2020 - thelancet.com
Background Ixekizumab, a high-affinity interleukin-17A (IL-17A) monoclonal antibody, has
previously shown efficacy in radiographic axial spondyloarthritis (also known as ankylosing …
previously shown efficacy in radiographic axial spondyloarthritis (also known as ankylosing …
A phase II randomized study of subcutaneous ixekizumab, an anti–interleukin‐17 monoclonal antibody, in rheumatoid arthritis patients who were naive to biologic …
…, M Greenwald, CS Cho, A Berman… - Arthritis & …, 2014 - Wiley Online Library
Objective To evaluate ixekizumab, an anti–interleukin‐17A (anti–IL‐17A) monoclonal
antibody, in 2 populations of rheumatoid arthritis (RA) patients: biologics‐naive patients and …
antibody, in 2 populations of rheumatoid arthritis (RA) patients: biologics‐naive patients and …
[PDF][PDF] Fenebrutinib versus placebo or Adalimumab in rheumatoid arthritis: A randomized, Double‐Blind, phase II trial
…, N Ramamoorthi, JA Hackney, A Berman… - Arthritis & …, 2020 - Wiley Online Library
Objective To evaluate fenebrutinib, an oral and highly selective noncovalent inhibitor of
Bruton's tyrosine kinase ( BTK ), in patients with active rheumatoid arthritis ( RA ). Methods …
Bruton's tyrosine kinase ( BTK ), in patients with active rheumatoid arthritis ( RA ). Methods …
The efficacy and safety of clazakizumab, an anti–interleukin‐6 monoclonal antibody, in a phase IIb study of adults with active psoriatic arthritis
PJ Mease, AB Gottlieb, A Berman… - Arthritis & …, 2016 - Wiley Online Library
Objective To evaluate the efficacy of clazakizumab, a monoclonal antibody with high affinity
and specificity for the interleukin‐6 (IL‐6) cytokine, in psoriatic arthritis (PsA). Methods In this …
and specificity for the interleukin‐6 (IL‐6) cytokine, in psoriatic arthritis (PsA). Methods In this …
The efficacy and safety of subcutaneous clazakizumab in patients with moderate‐to‐severe rheumatoid arthritis and an inadequate response to methotrexate: results …
…, T Takeuchi, E Drescher, A Berman… - Arthritis & …, 2015 - Wiley Online Library
Objective Clazakizumab is a humanized monoclonal antibody that binds to the interleukin‐6
(IL‐6) cytokine. This study was undertaken to evaluate the efficacy and safety of …
(IL‐6) cytokine. This study was undertaken to evaluate the efficacy and safety of …
Prevalence of rheumatoid arthritis in Tucumán, Argentina.
A Spindler, V Bellomio, A Berman, E Lucero… - The Journal of …, 2002 - jrheum.org
OBJECTIVE: To ascertain the prevalence of rheumatoid arthritis (RA) in Tucumán, Argentina.
METHODS: The study was conducted between January 1, 1998, and December 31, 1999, …
METHODS: The study was conducted between January 1, 1998, and December 31, 1999, …